Citation

Rozenek EB, Wilczyńska K, Górska M, Waszkiewicz N. Przegl. Epidemiol. 2019; 73(3): 337-347.

Affiliation

Medical University of Bialystok, Department of Psychiatry

Copyright

(Copyright © 2019, Panstwowy Zaklad Wydawnictw Lekarskich)

DOI

10.32394/pe.73.23

PMID

31766831

Abstract

INTRODUCTION: In Poland, an increasing number of psychoactive substances are becoming prohibited by law as psychotropic or narcotic substances, or as new psychoactive substances (NPSs). Owing to the enormous technological possibilities offered by today's science, synthesis of new derivatives of prohibited compounds is no longer a problem. The moment a dangerous substance is outlawed, new designer drugs (in Poland known as 'dopalacze') appear on the market. STATE OF KNOWLEDGE: An amendment to the Act on Counteracting Drug Addiction issued in July 2018 made it possible for the NPS to be considered drugs by law. Synthetic cannabinoids and cathinone derivatives make up the majority of NPSs identified by the authorities in Poland. Synthetic cannabinoids which can, unlike cannabinoid receptor agonists of plant origin, cause death by somatic toxicity, are particularly dangerous. The ability to quickly recognize poisoning with synthetic opioids is crucial, since an antidote reversing the depressive effect of opioids on the respiratory center can be administered. SUMMARY: This work collects the most important and up-to-date information on designer drugs, based on reports and articles published between 2015 and 2019. The covered aspects include: the current definition of designer drugs in relation to the Polish law, their exact division due to the clinical effects they cause and the description of the threats they pose. Emphasis was given to the current situation of the designer drug market in Poland.

National Institute of Public Health – National Institute of Hygiene

Language: en

Keywords

designer drugs; street drugs; drug design; hallucinogens; cannabinoids; opioids; benzodiazepines